Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published– Case Report Details 21 Months of ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Pediatrix Medical Group, Inc. (NYSE: MD) will host an investor conference call and webcast on Thursday, October 29, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended ...
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Health Canada has issued ...
A prospective cohort study finds that an appendicitis-compatible initial ultrasound report substantially improves diagnostic accuracy beyond age, Pediatric Appendicitis Score, and C-reactive protein ...
FONTANA: Phase I/IIa trial of torvutatug samrotecan (Torvu-Sam), a folate receptor α (FRα)-targeting ADC as monotherapy in patients with platinum-resistant recurrent ovarian cancer (Rapid Oral Session ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion ...
The presentations cover two FDA-approved antibiotics marketed by Innoviva Specialty Therapeutics, ceftobiprole (ZEVTERA ®) and zoliflodacin (NUZOLVENCE ® ), and represent the company’s ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results